Stimulatory effect of allantoin on imidazoline Ireceptors in animal and cell line

Hormone and Metabolic Research

Volumn 44, Issue 12, 2012, Pages 879-884

  Yang, T T ^a   Chiu, N H ^b   Chung, H H ^c   Hsu, C T ^d   Lee, W J ^e   Cheng, J T ^c,e,f  

^a I SHOU UNIVERSITY   (Taiwan)

^b HWA HSIA INSTITUTE OF TECHNOLOGY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d Edah University Medical Center   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

allantoin; blood pressure; efaroxan; farnesoid X receptor (FXR); imidazoline receptor; steatosis

Indexed keywords

ALLANTOIN; CHOLESTEROL; EFAROXAN; FARNESOID X RECEPTOR; HIGH DENSITY LIPOPROTEIN; IMIDAZOLINE I1 RECEPTOR; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FATTY LIVER; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ALLANTOIN; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BENZOFURANS; DIET, HIGH-FAT; FATTY LIVER; HEP G2 CELLS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; IMIDAZOLES; IMIDAZOLINE RECEPTORS; LIVER; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, LDL; UP-REGULATION;

ANIMALIA; MUS;

EID: 84869504731     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1312624     Document Type: Article

References (43)

1. Sagara K., Ojima M., Suto K., Yoshida T. Quantitative determination of allantoin in Dioscorea rhizome and an Oriental pharmaceutical preparation, hachimi-gan, by high-performance liquid chromatography. Planta Med: 1989; 55 93
2. Lee M. Y., Lee N. H., Jung D., Lee J. A., Seo C. S., Lee H., Kim J. H., Shin H. K. Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma. Int Immunopharmacol: 2010; 10 474 480
3. Shi Y. C., Liao J. W., Pan T. M. Antihypertriglyceridemia and anti-inflammatory activities of monascus-fermented dioscorea in streptozotocin-induced diabetic rats. Exp Diabetes Res: 2011; 2011 710635
4. Chang W. C., Yu Y. M., Wu C. H., Tseng Y. H., Wu K. Y. Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome. Can J Physiol Pharmacol: 2005; 83 423 430
5. Gao X., Li B., Jiang H., Liu F., Xu D., Liu Z. Dioscorea opposita reverses dexamethasone induced insulin resistance. Fitoterapia: 2007; 78 12 15
6. Hsu J. H., Wu Y. C., Liu I. M., Cheng J. T. Dioscorea as the principal herb of Die-Huang-Wan, a widely used herbal mixture in China, for improvement of insulin resistance in fructose-rich chow-fed rats. J Ethnopharmacol: 2007; 112 577 584
7. Shujun W., Jinglin Y., Wenyuan G., Hongyan L., Peigen X. New starches from traditional Chinese medicine (TCM) - Chinese yam (Dioscorea opposita Thunb.) cultivars. Carbohydr Res: 2006; 341 289 293
8. Niu C. S., Chen W., Wu H. T., Cheng K. C., Wen Y. J., Lin K. C., Cheng J. T. Decrease of plasma glucose by allantoin, an active principle of yam (Dioscorea spp.), in streptozotocin-induced diabetic rats. J Agric Food Chem 58 12031 12035
9. Aje T. O., Miller M. Cardiovascular disease: A global problem extending into the developing world. World J Cardiol: 2009; 1 3 10
10. McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep: 2008; 10 386 390
11. Lin K. C., Yeh L. R., Chen L. J., Wen Y. J., Cheng K. C., Cheng J. T. Plasma Glucose-lowering Action of Allantoin is Induced by Activation of Imidazoline I-2 Receptors in Streptozotocin-induced Diabetic Rats. Horm Metab Res: 2012; 44 41 46
12. Kaliszan W., Petrusewicz J., Kaliszan R. Imidazoline receptors in relaxation of acetylcholine-constricted isolated rat jejunum. Pharmacol Rep: 2006; 58 700 710
13. Morgan N. G., Chan S. L. Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Curr Pharm Des: 2001; 7 1413 1431
14. Prichard B. N., Graham B. R. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Drugs Aging: 2000; 17 133 159
15. Niu C. S., Wu H. T., Cheng K. C., Lin K. C., Chen C. T., Cheng J. T. A novel mechanism for decreasing plasma lipid level from imidazoline I-1 receptor activation in high fat diet-fed mice. Horm Metab Res: 2011; 43 458 463
16. Velliquette R. A., Kossover R., Previs S. F., Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol: 2006; 372 300 312
17. Chang C. H., Tsao C. W., Huang S. Y., Cheng J. T. Activation of imidazoline I(2B) receptors by guanidine to increase glucose uptake in skeletal muscle of rats. Neurosci Lett: 2009; 467 147 149
18. Chen M. F., Yang T. T., Yeh L. R., Chung H. H., Wen Y. J., Lee W. J., Cheng J. T. Activation of Imidazoline I-2B Receptors by Allantoin to Increase Glucose Uptake into C2C12 Cells. Horm Metab Res: 2012; 44 268 272
19. Eglen R. M., Hudson A. L., Kendall D. A., Nutt D. J., Morgan N. G., Wilson V. G., Dillon M. P. Seeing through a glass darkly: casting light on imidazoline I sites. Trends Pharmacol Sci: 1998; 19 381 390
20. Wang S. R., Pessah M., Infante J., Catala D., Salvat C., Infante R. Lipid and lipoprotein metabolism in Hep G2 cells. Biochim Biophys Acta: 1988; 961 351 363
21. Chapados N. A., Seelaender M., Levy E., Lavoie J. M. Effects of exercise training on hepatic microsomal triglyceride transfer protein content in rats. Horm Metab Res: 2009; 41 287 293
22. Ji W., Gong B. Q. Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats. J Ethnopharmacol: 2007; 113 318 324
23. Yang P. S., Wu H. T., Chung H. H., Chen C. T., Chi C. W., Yeh C. H., Cheng J. T. Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn Schmiedebergs Arch Pharmacol: 2012; 385 51 56
24. Cayla C., Schaak S., Roquelaine C., Gales C., Quinchon F., Paris H. Homologous regulation of the alpha2C-adrenoceptor subtype in human hepatocarcinoma, HepG2. Br J Pharmacol: 1999; 126 69 78
25. Charlton-Menys V., Durrington P. N. Human cholesterol metabolism and therapeutic molecules. Exp Physiol: 2008; 93 27 42
26. Sharma R., Long A., Gilmer J. F. Advances in bile acid medicinal chemistry. Curr Med Chem: 2011; 18 4029 4052
27. Claudel T., Staels B., Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol: 2005; 25 2020 2030
28. Trauner M., Claudel T., Fickert P., Moustafa T., Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis: 2010; 28 220 224
29. Lu T. T., Repa J. J., Mangelsdorf D. J. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem: 2001; 276 37735 37738
30. Zhang Y., Kast-Woelbern H. R., Edwards P. A. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem: 2003; 278 104 110
31. Evans M. J., Mahaney P. E., Borges-Marcucci L., Lai K., Wang S., Krueger J. A., Gardell S. J., Huard C., Martinez R., Vlasuk G. P., Harnish D. C. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol: 2009; 296 G543 G552
32. Kong B., Luyendyk J. P., Tawfik O., Guo G. L. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther: 2009; 328 116 122
33. Horton J. D., Goldstein J. L., Brown M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest: 2002; 109 1125 1131
34. Shimano H. Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm: 2002; 65 167 194
35. Watanabe M., Houten S. M., Wang L., Moschetta A., Mangelsdorf D. J., Heyman R. A., Moore D. D., Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest: 2004; 113 1408 1418
36. Goldberg I. J., Scheraldi C. A., Yacoub L. K., Saxena U., Bisgaier C. L. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem: 1990; 265 4266 4272
37. Murdoch S. J., Breckenridge W. C. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis: 1995; 118 193 212
38. Staels B., Vu-Dac N., Kosykh V. A., Saladin R., Fruchart J. C., Dallongeville J., Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest: 1995; 95 705 712
39. Kast H. R., Nguyen C. M., Sinal C. J., Jones S. A., Laffitte B. A., Reue K., Gonzalez F. J., Willson T. M., Edwards P. A. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol: 2001; 15 1720 1728
40. Claudel T., Inoue Y., Barbier O., Duran-Sandoval D., Kosykh V., Fruchart J., Fruchart J. C., Gonzalez F. J., Staels B. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology: 2003; 125 544 555
41. Blacklow S. C. Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. Curr Opin Struct Biol: 2007; 17 419 426
42. Ma P. T., Gil G., Südhof T. C., Bilheimer D. W., Goldstein J. L., Brown M. S. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA: 1986; 83 8370 8374
43. Soares E. A., Nakagaki W. R., Garcia J. A., Camilli J. A. Effect of hyperlipidemia on femoral biomechanics and morphology in low-density lipoprotein receptor gene knockout mice. J Bone Miner Metab: 2012; Jan 14 10.1007/s00774-011-0345-x